Replies to post #118975 on Biotech Values

[mcbio]

I reduced my position by 1/2. Move over, think I'll sit around with the rest and see how things develop.

There was so much buzz about the Intrexon platform (we'll find out in due time if warranted) when ZIOP did the deal with them that I would like to at least see some clinical data from one of the Intrexon drugs before I sell out of my position. I think there is some initial clinical data on the melanoma drug due later this year. That could create some buzz for ZIOP if the initial data is positive as that is of course just the tip of the Intrexon platform. I doubt any negative or ambiguous results from the initial Intrexon drug would have a really negative effect on ZIOP's stock since so much of the value of ZIOP has been attributed to palifosfamide and the rest of ZIOP's platform prior to the Intrexon deal. So, I view that initial Intrexon drug as kind of a low risk shot on goal given the rest of ZIOP's pipeline with the potential for nice upside if the data is positive.

BTW, I think Amrn is getting attractive again IMO. The intra-day low on the day it popped was around the mid $14's. I think that's where I will look to wet my beak again.

It might be but I tend to agree with the recent piece that AF did citing the run-up and fully-diluted share count as reasons for the stock possibly being reasonably valued at this point.